Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Publication describes how the unique qualities of ARCUS nucleases contribute to precise and efficient gene editing for gene ins...
Massachusetts General Hospital, Harvard Medical School, actively recruiting chronic hepatitis B patients along with multiple gl...
- Data to highlight latest long-term preclinical efficacy and durability data supporting PBGENE-DMD for the treatment of Duchen...
Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platfor...
Strengthens the Company's intellectual property portfolio for lead in vivo program PBGENE-HBV with U.S. patent protection i...
iECURE, Inc., a genome editing company focused on the development of variant-agnostic in vivo targeted gene insertion therapies...
Precision BioSciences (NASDAQ:DTIL) reported quarterly losses of $(2.13) per share which missed the analyst consensus estimate ...
